HIV感染者COVID-19的临床结局与免疫学特征
本研究回顾性分析HIV感染者(PWH)合并COVID-19的临床与免疫学特征。住院患者中26.4%(19/72)死亡,死亡者炎症标志物水平更高、淋巴细胞减少更严重。提示即使接受抗逆转录病毒治疗,PWH仍面临COVID-19重症风险。
要点
- HIV感染者合并COVID-19可出现严重淋巴细胞减少和CD4+ T细胞计数下降。
- 炎症标志物(CRP、纤维蛋白原、D-二聚体、IL-6、IL-8、TNF-α)常升高。
- 住院HIV感染者COVID-19死亡率为26.4%,死亡者炎症标志物更高、淋巴细胞减少更重。
核心结论
- HIV感染者即使接受抗逆转录病毒治疗,仍面临COVID-19重症风险。
- 炎症标志物升高和免疫失调者预后更差。
研究设计与样本
- 回顾性研究,纳入HIV感染者合并COVID-19,其中住院患者72例。
主要发现
- HIV感染者合并COVID-19出现严重淋巴细胞减少和CD4+ T细胞计数下降。
- 炎症标志物包括C反应蛋白、纤维蛋白原、D-二聚体、白介素6、白介素8和肿瘤坏死因子α常升高。
- 72例住院患者中19例(26.4%)死亡,53例(73.6%)康复。
- 死亡者炎症标志物水平更高、淋巴细胞减少更严重。
临床怎么用
- 对HIV感染者合并COVID-19应监测淋巴细胞计数和炎症标志物。
- 炎症标志物升高和免疫失调者需警惕更差结局。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a retrospective study of coronavirus disease 2019 (COVID-19) in people with human immunodeficiency virus (PWH). PWH with COVID-19 demonstrated severe lymphopenia and decreased CD4+ T cell counts. Levels of inflammatory markers, including C-reactive protein, fibrinogen, D-dimer, interleukin 6, interleukin 8, and tumor necrosis factor α were commonly elevated. In all, 19 of 72 hospitalized individuals (26.4%) died and 53 (73.6%) recovered. PWH who died had higher levels of inflammatory markers and more severe lymphopenia than those who recovered. These findings suggest that PWH remain at risk for severe manifestations of COVID-19 despite antiretroviral therapy and that those with increased markers of inflammation and immune dysregulation are at risk for worse outcomes.
引用
- Ho HE, Peluso MJ, Margus C, et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. J Infect Dis. 2021. PMID: 32601704. doi:10.1093/infdis/jiaa380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。